Search Results
Your search for all items matches 236 pages
Showing 1 - 50
Julie Gralow, MD, FACP, FASCO, on Conserving IV Fluid Supplies During Natural Disasters
The nation’s intravenous fluid shortage was exacerbated this week when flooding from Hurricane Helene damaged a Baxter International plant in North Cove, North Carolina, which makes about 60% of the United States’ supply of fluids used in IVs for patients with a variety of diseases, including...
Andrew Srisuwananukorn, MD, and Alexander T. Pearson, MD, PhD, on Artificial Intelligence in the Clinic: Understanding How to Use This 21st Century Tool
Andrew Srisuwananukorn, MD, of The Ohio State University, and Alexander T. Pearson, MD, PhD, of the University of Chicago, discuss the use of artificial intelligence (AI) in the clinic, its potential benefits in diagnosis and treatment, resources available to help physicians learn more about AI,...
Sara Khan, DO, on the Gender Gap in Receiving NIH Grants for Hematology Research
Sara Khan, DO, of the University of South Florida Morsani College of Medicine and HCA Healthcare, discusses her findings showing that women received only 33% of grants from the National Institutes of Health from 2012 to 2022 in nonmalignant hematologic research. Although some agencies have made...
Aki Morikawa, MD, PhD, on Brain Metastases: New Findings on Predictive Drug Testing
Aki Morikawa, MD, PhD, of the University of Michigan, and her team explored the use of patient-derived organoids from breast cancer brain metastases to evaluate drug sensitivities in a clinically meaningful time frame. Along with molecular profiling, she says, this method may further personalize...
Wei Wu, MD, PhD, on Lung Cancer: Deep Learning as a Tool for Identifying Drug-Tolerant Persister Cells
Wei Wu, MD, PhD, of the University of California, San Francisco, discusses new findings that suggest his team’s deep learning neural network model may be able to identify subpopulations of patients with lung cancer who have YAP1-activated tumors and drug-tolerant persister cells. These patients may ...
Carmen E. Guerra, MD, MSCE, on Diversity, Equity, and Inclusion in Clinical Trials: Expert Commentary
Carmen E. Guerra, MD, MSCE, of the University of Pennsylvania Abramson Cancer Center, discusses three key abstracts presented at ASCO: strategies to increase accrual of underrepresented populations in Alliance NCTN trials, how patient-clinician education can strengthen partnerships and improve...
Carmen E. Guerra, MD, MSCE, on Strategies for Equitable Access to Cancer Clinical Trials
Carmen E. Guerra, MD, MSCE, of the University of Pennsylvania Abramson Cancer Center, discusses the ways in which community outreach, programs to help patients access cancer clinical trials, and institutional policies such as ASCO’s Just Ask program can help increase equity, diversity, and...
Harry Klein, PhD, on MatchMiner: An Open-Source AI Precision Medicine Trial Matching Platform
Harry Klein, PhD, of Dana-Farber Cancer Institute, discusses MatchMiner, a software platform launched in 2017, that matches patients with appropriate clinical trials of targeted therapies. The platform uses data on the genetic features of a patient’s cancer, as well as clinical data, to identify...
Karriem S. Watson, DHSc, on Early Engagement in Clinical Trials for Underrepresented Communities
Karriem S. Watson, DHSc, MPH, of the National Institutes of Health All of Us Research Program, discusses the importance of engaging in clinical trials for those who are underrepresented in biomedical research. Community engagement is a proven and effective tool, Dr. Watson says, to enhance...
Mandi L. Pratt-Chapman, PhD, on Oncology Care in the LGBTQI+ Community: Best Practices for Addressing Health Needs
Mandi L. Pratt-Chapman, PhD, of the George Washington University Cancer Center, discusses the specific health-care needs for cancer screening, treatment, and survivorship among members of the LGBTQI+ community. Because clinical practices and research studies do not routinely collect sexual...
Jamie Takayesu, MD, on Genitourinary Cancer: Disparity in Physicians’ Assessment of Sexual Dysfunction in Women vs Men
Jamie Takayesu, MD, of the University of Michigan, discusses her findings on how frequently physicians are asking their female and male patients with genitourinary cancers about sexual dysfunction. Although 62.79% of women with genitourinary cancer who received brachytherapy thought they should be ...
Emily C. Daugherty, MD, on FLASH Radiotherapy: Efficacy and Safety Results From the First-in-Human Study
Emily C. Daugherty, MD, of the University of Cincinnati, discusses results from the FAST-01 study, which showed that FLASH proton radiotherapy, delivered at ultra-high–dose rates, may be efficacious, with adverse events comparable to conventional dose-rate treatment of patients with cancer....
Abdul Rahman Al Armashi, MD, on AML: Racial Disparities in Mortality Trends
Abdul Rahman Al Armashi, MD, of Seidman Cancer Center, Case Western University, University Hospitals Cleveland Medical Center, discusses a retrospective analysis, using a CDC database, in one of the largest subgroup-based racial population studies analyzing mortality trends in patients with acute...
Samyukta Mullangi, MD, MBA, on Predictors of Compliance With Payer-Led Oncology Clinical Pathways
Samyukta Mullangi, MD, MBA, of Memorial Sloan Kettering Cancer Center, discusses her findings showing that physicians’ prescribing behavior may be influenced by payer-led pathways. Pathway compliance was associated with higher medical costs during a 6-month baseline period but lower health-care...
Regina Barragán-Carrillo, MD, on Breast Cancer Screening in the Transgender Population
Regina Barragán-Carrillo, MD, of Mexico’s National Institute of Medical Sciences and Nutrition Salvador Zubirán, discusses her findings showing that currently, physicians have limited knowledge about breast cancer screening in transgender patients. Were this topic addressed with widespread...
Jensa C. Morris, MD: Oncology Hospitalist Co-Management May Be Linked to Efficient, High-Quality Care and Education
Jensa C. Morris, MD, of the Yale School of Medicine, Smilow Hospitalist Service, discusses her findings on the benefits of hospitalist co-management of patients with cancer: It reduced the length of hospital stay by 1 day, increased early discharge (before 11:00 AM) by threefold; raised the...
Joannie M. Ivory, MD, MSPH, on Increasing Participation of Black Patients With Cancer in Clinical Trials
Joannie M. Ivory, MD, MSPH, of The University of North Carolina at Chapel Hill, discusses ways to raise the number of Black patients with cancer who take part in clinical trials. More successful accrual may be linked to conducting trials where Black patients live and designing studies to recruit a...
Changchuan Jiang, MD, MPH, on Transportation Barriers, Delays in Cancer Care, and Increased Mortality for Patients With Cancer
Changchuan Jiang, MD, MPH, of Roswell Park Comprehensive Cancer Center, discusses the lack of transportation as a potentially modifiable barrier to care for patients with cancer. Timely intervention may reduce visits to hospital emergency departments, lower costs, and improve outcomes (Abstract 70).
Dawn L. Hershman, MD, on Prophylactic Colony Stimulating Factors for Neutropenia: Improving Clinicians’ Prescribing Practices
Dawn L. Hershman, MD, of Columbia University College of Physicians and Surgeons, discusses findings that showed substantial variability in clinicians’ adherence to prescribing primary prophylactic colony stimulating factors in a pragmatic trial. Although the ability to opt out of the intervention...
Clifford A. Hudis, MD, and Karen E. Knudsen, PhD, MBA, on How ASCO and the American Cancer Society Are Collaborating to Help Patients With Cancer
Clifford A. Hudis, MD, of the American Society of Clinical Oncology, and Karen E. Knudsen, PhD, MBA, of the American Cancer Society, discuss their collaboration, pooling their research and education resources to help empower patients with cancer and their families. Within 48 hours, Drs. Hudis and...
Nickolas Papadopoulos, PhD, on Multicancer Early Detection: Opportunities and Challenges
Nickolas Papadopoulos, PhD, of the Sidney Kimmel Comprehensive Cancer Center, discusses early detection as the key to reducing cancer mortality and the lack of tests for many malignancies. Liquid biopsies have the potential to screen for various tumor types, albeit with varying levels of...
Maria Alma Rodriguez, MD, on Vaccinations for Patients With Cancer and Cancer Survivors
Maria Alma Rodriguez, MD, of The University of Texas MD Anderson Cancer Center, discusses the need for various types of vaccinations in patients with cancer, who are vulnerable to infection while under active treatment and whose immune deficits may persist long after treatment is finished. Dr....
Charles L. Sawyers, MD, on Transforming Patient Outcomes: The Future of Cancer Research
Charles L. Sawyers, MD, of Memorial Sloan Kettering Cancer Center, discusses the battle against treatment resistance and how to overcome it, as well as the power of observational clinical data in precision oncology, derived largely from his experience with Project GENIE, and the role of genetic...
Priscilla K. Brastianos, MD, on CNS Metastases: Understanding Their Evolution and the Clinical Implications
Priscilla K. Brastianos, MD, of Harvard Medical School and Massachusetts General Hospital, talks about her efforts to better understand how brain metastases evolve genomically and to test such agents as abemaciclib, paxalisib, and entrectinib, which may stop their growth. Palbociclib, a CDK...
Timothy A. Yap, MBBS, PhD, on Developing Novel Therapeutic Strategies to Target DNA Damage Response in the Clinic
Timothy A. Yap, MBBS, PhD, of The University of Texas MD Anderson Cancer Center, discusses how research is building on the success of first-generation PARP inhibitors in the clinic and the potential of novel potent PARP1-selective inhibitors, which may lead to improved patient outcomes. Given...
Lillian L. Siu, MD, on Looking Toward the Future of Clinical Research and Clinical Trials
Lillian L. Siu, MD, of Canada’s Princess Margaret Cancer Centre, discusses biomarker-driven precision cancer medicine, the optimal sequencing of immunotherapy (IO) with standard treatments in curative settings, IO targets beyond PD-1/PD-L1 and combinatorial strategies, and next-generation adoptive...
Marcia R. Cruz-Correa, MD, PhD, on a Vision for the Future of Cancer Research and Treatment
Marcia R. Cruz-Correa, MD, PhD, of the University of Puerto Rico Comprehensive Cancer Center, discusses a way to possibly transform cancer outcomes by teaming up basic scientists, clinical researchers, and community advocates to work together, decode the complexity of cancer, and find points at...
Cheryl L. Willman, MD, on Cancer Genomic Sequencing in Tribal Nations of the American Southwest
Cheryl L. Willman, MD, of the Mayo Clinic Comprehensive Cancer Center, discusses the profound cancer health disparities among Native Americans, exacerbated by low rates of screening and limited access to care. Dr. Willman is heading an effort to promote community engagement in comprehensive genomic ...
Gautam Mehta, MD, on Precision Oncology: An Overview of the Accelerated Approval Program
Gautam Mehta, MD, of the U.S. Food and Drug Administration, discusses how accelerated approval of potentially life-saving cancer therapies has been applied in precision oncology. Although “fast-tracking” drugs presents opportunities and challenges, one possible measure of the program’s success is...
Electra D. Paskett, PhD, on Social Stresses and Cancer Treatment: An Expert Perspective
Electra D. Paskett, PhD, of The Ohio State University, discusses various factors that may contribute to cancer such as socioeconomic status, discrimination, violence, and access to health care. When clinicians identify these factors and intervene with access to services, it may be possible to...
Klaus Pantel, MD, on Liquid Biopsy Research: Opportunities and Challenges
Klaus Pantel, MD, of the University Medical Center Hamburg-Eppendorf, discusses liquid biopsy technologies and biomarkers, with a focus on circulating tumor cells and circulating tumor DNA; clinical applications such as early detection of cancer, improved staging, and surveillance of measurable...
Vivek Subbiah, MD, on Designing Clinical Trials for Precision Oncology
Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, talks about innovative design of clinical studies that may help demonstrate clinical benefit in precision medicine and advance treatment to deliver the right intervention to the right patient at the right time (Abstract DC06).
Karen E. Knudsen, PhD, MBA, on Addressing Disparities in Genitourinary Cancers
Karen E. Knudsen, PhD, MBA, Chief Executive Officer of the American Cancer Society, discusses ways to address the inequities in genitourinary screening, treatment, and outcomes. Her suggestions focus on increasing awareness of screening, identifying risk factors, the dramatic rise in incidence...
Lynda Chin, MD, on the Landscape and Future of Digital Medicine
Lynda Chin, MD, of the University of Texas, Austin Dell Medical School and Apricity Health, discusses precision medicine, barriers to its progress, and the challenges that must be met to facilitate better outcomes for patients. Building evidence and trust is key, Dr. Chin explains, as is developing ...
Sean Khozin, MD, MPH, on Delivering Precision Cancer Care in the Era of Digital Medicine
Sean Khozin, MD, MPH, of CancerLinQ, discusses the therapeutic advances that have made cancer care more targeted, even as real-world patient outcomes lag behind those reported in clinical trials. Dr. Khozin makes the case for the use of digital decision support tools to advance precision at the...
Daniel F. Hayes, MD, on Liquid Biopsies to Detect and Monitor Oligometastases
Daniel F. Hayes, MD, of the University of Michigan Rogel Cancer Center, discusses whether liquid biopsies can provide insight into the challenge of curing metastatic breast and possibly other cancers, how oligometastases are similar to a primary cancer, and why some kinds of local therapy for...
Matthew Manning, MD, on Resolving Racial Disparities in the Treatment of Breast and Lung Cancers
Matthew Manning, MD, of Cone Health Cancer Center, discusses findings that showed changes to the way cancer care is delivered may help eliminate racial disparities in survival among patients with early-stage lung and breast cancers. Identifying and addressing obstacles that kept patients from...
Karen M. Winkfield, MD, PhD, on Digital Health to Improve Patient Outcomes and Experience
Karen M. Winkfield, MD, PhD, of Vanderbilt University Medical Center, who co-chaired a session (PS 02) on digital health, summarizes the talks, which included ways to reduce disparities with digital innovations and the importance of patient input, especially in the form of patient-reported outcomes ...
Morgan R.L. Lichtenstein, MD, on Insurance Plan, Prior Authorization, and Time to Receipt of Oral Anticancer Drugs
Morgan R.L. Lichtenstein, MD, of Columbia University Medical Center, discusses a single-center prospective study examining the complex relationship between time to oral oncolytic receipt and clinical or process-related factors, such as prior authorization, diagnosis, and insurance type.
Aakash Desai, MPH, MD, on the Precision Oncology Promise: Can We Deliver?
Aakash Desai, MPH, MD, of the Mayo Clinic in Rochester, Minnesota, talks about the urgent need for drug pricing reform, given the average expenditure of Medicare part D, and the ultimate out-of-pocket costs for patients with cancer. The promise of precision oncology will fail, says Dr. Desai, if we ...
Jenny Jing Xiang, MD, on Improving Clinical Trial Recruitment With a Universal Prescreening Protocol
Jenny Jing Xiang, MD, of Yale University School of Medicine, discusses a universal, standardized clinical trial prescreening protocol, which streamlined research recruitment and was associated with yearly increases in patient enrollment at the Veterans Administration (VA) Connecticut Cancer Center. ...
Joseph M. Unger, PhD, on the Impact of NCI-Sponsored Treatment Trials
Joseph M. Unger, PhD, of Fred Hutchinson Cancer Research Center, discusses findings from his study of the National Cancer Institute’s Clinical Trials Network, which has conducted publicly funded cancer research for more than 50 years. The substantial gains in life years for patients with cancer, he ...
John V. Cox, DO, MBA, on Reshaping Practice Models to Better Care for Patients With Cancer
John V. Cox, DO, MBA, of The University of Texas Southwestern Medical Center, summarizes his Joseph V. Simone Lecture, in which he stressed the need for coordinated care among practices. The concept of oncology medical homes, he says, has evolved to a broader-based model in which oncologists...
Divya Gupta, MD, on Improving Advance Care Planning Conversations With Patients
Divya Gupta, MD, of the Stanford Cancer Center, discusses an intervention utilizing a computer model and lay care coaches to improve advance care planning conversations with patients who have metastatic cancer. The study, Dr. Gupta reports, showed a trend toward less intensive care for patients at...
Divya A. Parikh, MD, on Improving Care Documentation With a Patient Conversation Guide
Divya A. Parikh, MD, of Stanford University School of Medicine, discusses findings that suggest an evidence-based tool, the Serious Illness Conversation Guide, may engage patients with metastatic or recurrent urologic cancer in goals-of-care conversations, potentially resulting in an increase of...
Courtney Williams, DrPH, on Cancer Survivors: Working Together to Improve Patient Adherence
Courtney Williams, DrPH, of the National Cancer Institute, discusses the costs associated with cancer survivors who don’t take their medications and cites the need for research to better understand whether residing in an urban or rural area may affect prescription adherence, and what interventions...
Benjamin W. Corn, MD, on Integrating Hope Into Clinical Oncology
Benjamin W. Corn, MD, of Shaare Zedek Medical Center in Jerusalem, discusses hope: what it takes for hope to thrive; how he and his colleagues are helping patients and providers become more hopeful through workshops; and his collaboration with the Southwest Oncology Group to aid patients, through...
Sarah S. Mougalian, MD, on a Next-Day Access Program for Patients With Cancer
Sarah S. Mougalian, MD, of Yale Cancer Center, discusses the increasingly common problem of long wait times for access to oncology care. Her team developed a next-day access program in several of Yale’s oncology services, which was well received by patients and decreased the time to first visit.
Manali I. Patel, MD, MPH, on Community-Based Intervention and Cancer Care Disparity
Manali I. Patel, MD, MPH, of Stanford University School of Medicine, discusses data suggesting that community health workers and innovative payer models can better engage low-income and minority patients with cancer, improve their health-related quality of life, and reduce unwanted and unnecessary...
Neeraj Agarwal, MD, on Treatment Patterns and Disparities in Patients With Prostate Cancer
Neeraj Agarwal, MD, of Huntsman Cancer Institute at the University of Utah, discusses three studies that examined real-world treatment patterns and utilization of advanced therapies in men with metastatic castration-sensitive prostate cancer, which served to highlight the ways in which Black men...
